May 2018
Welcome to the May issue. Find out how an edible QR code could help fight fake medicine, and why funding is being offered to develop a universal flu vaccine. And in In My View, Misagh Naderi and Jeremy Drummond argue the case for drug repurposing for rare diseases and the eye, respectively. Our cover feature takes a look at the current state of the biosimilars field – and the myths preventing wider use – with experts from across the industry. NextGen explores a collaboration planning to use machine learning to accelerate drug discovery, and finally, we sit down with Cyrus Krakaria, President of Biotechnology for Lupin Limited.
Easy as B to D?
May 11, 2018
The Trump Administration’s plans to move Medicare Part B drugs into the Part D system, and to change Part D formulary standards to require a minimum of one drug per category rather than two, would mean additional delays and cost barriers for patients.
1 min read
Land of Opportunity
May 10, 2018
Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.
1 min read
Biosimilar Backer
May 9, 2018
Sitting Down With… Cyrus Krakaria, President of Biotechnology at Lupin Limited, Biotech Division, India.
1 min read
Recognizing Friend from Foe
May 9, 2018
The immune system scrambles into action when a foreign entity is detected, but not all foreign entities mean harm. New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.
1 min read
Business & Regulation
Facilities & Equipment
Technology & Manufacturing
Development & Clinical
Business & Trends
Medicina Ex Machina
May 9, 2018
The sci-fi inspired concern that artificial intelligence will one day rule the world is (mostly) unfounded, but it certainly could have a huge impact on drug discovery.
1 min read
What Regulators Want
May 9, 2018
By Bruno Speder, Head Clinical Regulatory Affairs & Consultancy at SGS
1 min read
I’m a (Biosimilars) Believer!
May 9, 2018
It’s been a long winding journey, but biosimilars are finally starting to shake up the biopharma market. Their true potential remains untapped, however – hindered by market access and myths around safety. Here, four biosimilar gurus discuss successes and tackle the issues head on.
1 min read
Industrializing Cell Therapy
May 9, 2018
We know that cell therapies work; now, we need to learn to manufacture them efficiently on an industrial scale.
1 min read
It Doesn’t Have To End In Tears
May 9, 2018
Rare diseases aren’t the only field that can benefit from repurposing – companies should also consider breathing new life into old drugs for a much overlooked organ: the eye.
1 min read
Old Drugs, New Computational Tools
May 9, 2018
Drug repurposing can benefit many areas of drug discovery – particularly rare diseases.
1 min read
Stay Ahead. Smart Risk Management
May 9, 2018
As supply chains become increasingly complex, collaboration between biopharmaceutical customers and suppliers is crucial for supply continuity and control.
1 min read
Get ‘Em While They’re Young
May 9, 2018
Pharmacy students take medicine safety lessons to school classrooms
1 min read
Business in Brief
May 9, 2018
A knockback for biosimilars in the US, patient engagement, and contaminated blood products… What’s new for pharma in business?
1 min read
Staying on Target
May 9, 2018
What characteristics make a cancer therapy more likely to effectively treat disease?
1 min read
A Life Too Short
May 9, 2018
Researchers celebrate a new breakthrough into progeria, and urge others to help them find a cure
1 min read
Go Forth and Find a Flu Vaccine!
May 9, 2018
Bill Gates has issued a challenge – and significant funding – to help researchers push for a universal flu vaccine
1 min read
Wake Up and Smell the Polymer
May 9, 2018
Caffeine isn’t just a catalyst to get you moving in the morning – it can also help create polymers for drug delivery
1 min read
Print it, Eat it
May 9, 2018
Could drug-containing QR codes fight fakes and avoid medication errors?
1 min read
Open Your Mind
May 9, 2018
Is the pharmaceutical industry overly reluctant to accept new ideas?
1 min read
